June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Choroidal Angiographic Feature Associated with Persistent Subretinal Fluid in Central Serous Chorioretinopathy
Author Affiliations & Notes
  • Takahiro Kogo
    Department of Ophthalmology and Visual Sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Yuki Muraoka
    Department of Ophthalmology and Visual Sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Masaharu Ishikura
    Department of Ophthalmology and Visual Sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Naomi Nishigori
    Department of Ophthalmology and Visual Sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Naoko Ueda
    Department of Ophthalmology and Visual Sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Manabu Miyata
    Department of Ophthalmology and Visual Sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Hiroshi Tamura
    Department of Ophthalmology and Visual Sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Masayuki Hata
    Department of Ophthalmology and Visual Sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Ayako Takahashi
    Department of Ophthalmology and Visual Sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Masahiro Miyake
    Department of Ophthalmology and Visual Sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Akitaka Tsujikawa
    Department of Ophthalmology and Visual Sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Footnotes
    Commercial Relationships   Takahiro Kogo None; Yuki Muraoka Bayer Yakuhin, Novartis Pharma KK, Code F (Financial Support), Bayer Yakuhin, Novartis Pharma KK, Canon, Santen Pharmaceutical, Senju Pharmaceutical, Code R (Recipient); Masaharu Ishikura None; Naomi Nishigori None; Naoko Ueda Santen Pharmaceutical, Novartis Pharma KK, Chugai Pharmaceutical, Code R (Recipient); Manabu Miyata Alcon Japan, Novartis Pharma KK, Santen Pharmaceutical, Code F (Financial Support), Santen Pharmaceutical, HOYA, Bayer Yakuhin, Senju Pharmaceutical, Kowa Pharmaceutical, Code R (Recipient); Hiroshi Tamura Findex, Code F (Financial Support), Bayer Yakuhin, Novartis Pharma KK, Santen Pharmaceutical, SUNTORY, Otsuka Pharmaceutical, Code R (Recipient); Masayuki Hata Novartis Pharma KK, Code F (Financial Support), Kyoto Drug Discovery & Development, Code P (Patent), Senju Pharmaceutical, Code R (Recipient); Ayako Takahashi Bayer Yakuhin, Novartis Pharma, Santen Pharmaceutical, MSD, Code R (Recipient); Masahiro Miyake Novartis Pharma KK, Code F (Financial Support), Novartis Pharma KK, Bayer Yakuhin, Kowa Pharmaceutical, Alcon Japan, AMO Japan, Santen Pharmaceutical, Senju Pharmaceutical, Johnson & Johnson K. K., Chugai Pharmaceutical, Code R (Recipient); Akitaka Tsujikawa Senju Pharmaceutical,Bayer Yakuhin,Novartis Pharma,HOYA,Ellex,Allegan Japan,Eisai,Daiich-Sankyo,Chugai Pharmaceutical,MSD, Code C (Consultant/Contractor), Canon,Findex,Santen Pharmaceutical,Kowa Pharmaceutical,Pfizer,AMO Japan,Senju Pharmaceutical,Wakamoto Pharmaceutical,Alcon Japan,Novartis Pharma,Otsuka Pharmaceutical,Bayer Yakuhin,Nitten Pharmaceutical, Code F (Financial Support), Bayer Yakuhin,Senju Pharmaceutical,Novartis Pharma,Santen Pharmaceutical,Alcon Pharma,Alcon Japan,AbbVie GK,AMO Japan,Kowa Pharmaceutical,Canon,Otsuka Pharmaceutical,Wakamoto Pharmaceutical, Code R (Recipient)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, OD85. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Takahiro Kogo, Yuki Muraoka, Masaharu Ishikura, Naomi Nishigori, Naoko Ueda, Manabu Miyata, Hiroshi Tamura, Masayuki Hata, Ayako Takahashi, Masahiro Miyake, Akitaka Tsujikawa; Choroidal Angiographic Feature Associated with Persistent Subretinal Fluid in Central Serous Chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2023;64(8):OD85.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The subretinal fluid (SRF) associated with central serous chorioretinopathy (CSC) can spontaneously resolve within a few months. However, the SRF can recur or persist, impairing visual function. Recent developments in optical coherence tomography (OCT), especially enhanced depth imaging (EDI) and swept-light source (SS), have facilitated the evaluation of choroidal vasculature. This evaluation suggests that congestive flow in the vortex veins might be involved in CSC development. However, the wide field (WF) choroidal vasculature associated with the CSC-SRF has not been fully elucidated. We analyzed the EDI of WF SS-OCT data of the choroid of eyes with CSC and examined the choroidal angiographic features in the posterior pole that could predict the resolution or prolongation of the SRF.

Methods : We included twenty-nine patients with treatment-naïve CSC, and observed for more than three months without treatment. Using EDI of WF SS-OCT (Xephilio OCT-S1, Canon Inc.), the choroidal thickness (CT), vessel density (VD), vessel length density (VLD), and vessel diameter index (VDI) in the superotemporal and inferotemporal subfields of the 18-mm-diameter circle centered on the fovea were measured at the initial visit. The patients were divided into two groups based on the presence (SRF-persistent group) or absence (SRF-resolved group) of SRF three months after the initial visit (Month 3). We calculated the vertical differences in CT and other choroidal angiographic parameters and evaluated their association with the SRF condition at Month 3.

Results : The SRF-resolved and SRF-persistent groups included 10 and 19 patients, respectively. At the initial visit, sex, age, axial length, symptom duration, logarithm of minimum angle of resolution visual acuity, and retinal thickness at the fovea were not different between the two groups. No significant association was observed between SRF status at Month 3 and the vertical differences in CT, choroidal VD, and VLD (P = 0.534, 0.094, 0.092, respectively). However, the vertical difference in choroidal VDI was positively associated with SRF presence (P < 0.001).

Conclusions : In eyes with CSC, dilated choroidal vessels in the posterior pole may be a biomarker associated with SRF; the vertically asymmetrical choroidal dilation may be a good predictor of SRF-status.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×